Fexclu reimb at ₩939, Kadcyla reimb extended from July
By Kim, Jung-Ju | translator Alice Kang
22.06.28 13:13:04
°¡³ª´Ù¶ó
0
MOHW puts agenda up for 14th HIPDC meeting¡¦ passes deliberations
Four items including Daewoong Pharmaceutical¡¯s Fexclu Tab (fexuprazan hydrochloride) will be listed at ₩939 per tablet starting next month as latecomers of the homegrown novel drug K-CAB indicated to treat erosive gastroesophageal reflux disease (GERD).
Also, reimbursement of Kadcyla (trastuzumab emtansine), Roche Korea¡¯s second-line treatment for breast cancer, will be extended to cover its treatment as ¡®adjuvant treatment of patients with early breast cancer after surgery¡¯, and will accordingly receive a new drug price.
The Ministry of Health and Welfare held the 14th Health Insurance Policy Deliberation Committee meeting (Chair: 2nd Vice Minister of Health and Welfare, Ki-Il Lee
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)